Celgene Corp. (NASDAQ:CELG) was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating in a research note issued on Tuesday. The brokerage currently has a $128.85 target price on the biopharmaceutical company’s stock. Vetr‘s price target points to a potential upside of 8.73% from the stock’s current price.

Several other brokerages also recently commented on CELG. BTIG Research restated a “buy” rating and issued a $138.00 target price on shares of Celgene Corp. in a research note on Sunday, August 21st. BMO Capital Markets restated an “outperform” rating and issued a $141.00 target price on shares of Celgene Corp. in a research note on Monday, October 3rd. JPMorgan Chase & Co. restated an “overweight” rating and issued a $136.00 target price on shares of Celgene Corp. in a research note on Friday, August 19th. Jefferies Group restated a “buy” rating and issued a $134.00 target price on shares of Celgene Corp. in a research note on Monday, October 17th. Finally, Bank of America Corp. restated a “buy” rating and issued a $128.00 target price on shares of Celgene Corp. in a research note on Friday, September 16th. Four analysts have rated the stock with a hold rating and twenty-seven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $136.77.

Analyst Recommendations for Celgene Corp. (NASDAQ:CELG)

Celgene Corp. (NASDAQ:CELG) opened at 118.51 on Tuesday. The stock has a 50 day moving average price of $108.88 and a 200 day moving average price of $106.73. The firm has a market cap of $91.87 billion, a P/E ratio of 45.01 and a beta of 1.71. Celgene Corp. has a 1-year low of $93.05 and a 1-year high of $127.00.

Celgene Corp. (NASDAQ:CELG) last issued its earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.48 by $0.10. Celgene Corp. had a return on equity of 70.48% and a net margin of 19.71%. The business earned $2.98 billion during the quarter, compared to the consensus estimate of $2.84 billion. During the same quarter last year, the company earned $1.23 EPS. The firm’s revenue was up 27.8% compared to the same quarter last year. On average, analysts anticipate that Celgene Corp. will post $5.92 EPS for the current year.

TRADEMARK VIOLATION WARNING: This story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The original version of this story can be read at https://www.thecerbatgem.com/2016/12/01/celgene-corp-celg-rating-increased-to-buy-at-vetr-inc.html.

In other news, Director Gilla Kaplan sold 9,710 shares of the company’s stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $106.44, for a total transaction of $1,033,532.40. Following the transaction, the director now directly owns 72,142 shares of the company’s stock, valued at $7,678,794.48. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Richard W. Barker sold 20,000 shares of the company’s stock in a transaction on Friday, September 23rd. The shares were sold at an average price of $110.82, for a total value of $2,216,400.00. Following the transaction, the director now directly owns 31,332 shares in the company, valued at $3,472,212.24. The disclosure for this sale can be found here. Insiders own 0.97% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Fulton Bank N.A. increased its position in shares of Celgene Corp. by 0.3% in the second quarter. Fulton Bank N.A. now owns 29,054 shares of the biopharmaceutical company’s stock worth $2,866,000 after buying an additional 86 shares during the last quarter. Kistler Tiffany Companies LLC increased its position in shares of Celgene Corp. by 4.4% in the second quarter. Kistler Tiffany Companies LLC now owns 6,020 shares of the biopharmaceutical company’s stock worth $594,000 after buying an additional 255 shares during the last quarter. Boltwood Capital Management increased its position in shares of Celgene Corp. by 7.3% in the second quarter. Boltwood Capital Management now owns 5,795 shares of the biopharmaceutical company’s stock worth $572,000 after buying an additional 395 shares during the last quarter. Integrated Investment Consultants LLC increased its position in shares of Celgene Corp. by 21.8% in the second quarter. Integrated Investment Consultants LLC now owns 1,339 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 240 shares during the last quarter. Finally, Cullinan Associates Inc. increased its position in shares of Celgene Corp. by 23.5% in the second quarter. Cullinan Associates Inc. now owns 62,007 shares of the biopharmaceutical company’s stock worth $6,116,000 after buying an additional 11,800 shares during the last quarter. 76.43% of the stock is currently owned by hedge funds and other institutional investors.

About Celgene Corp.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Receive News & Stock Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related stocks with our FREE daily email newsletter.